Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, April 06, 2022
INCOG BioPharma Services, an Indiana-based contract development and manufacturing organization (CDMO) has completed the construction of its cleanroom production area within the new 90,000ft2 biopharma manufacturing site.
read more
INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, will feature Pierre Geoffroy, PhD, Vice President, Early Phase to discuss ethical principles related to ...
read more
Wednesday, January 24, 2018
Imprimis announced its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate.
read more
Thursday, December 21, 2017
Impax Laboratories has entered into a definitive agreement to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals.
read more
Tuesday, December 29, 2020
Immutep has prioritized the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha.
read more
Imanova has signed an agreement that grants the company the right to manufacture for distribution and on-site use [18F]MK-6240, an early stage investigational PET imaging agent.
read more
Wednesday, August 29, 2018
ImaginAb and CPDC announced they have entered into a development and manufacturing agreement for the supply of ImaginAb's clinical-phase PET imaging agent Zr-89 IAB22M2C to key global geographies.
read more
ImaBiotech Group announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc. Colorado Springs and Salt Lake City sites. The integration of the expertise, innovation and analytical platforms of the companies to form a ...
read more
Monday, November 11, 2013
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received formal approval from the U.S. Food and Drug Administration (FDA) of its supplemental filing for the site transfer of ...
read more
Wednesday, November 06, 2013
Jason Grenfell-Gardner, President and CEO of the Company, commented, "This submission brings our total number of abbreviated new drug applications on file with the FDA to thirteen. We believe our current pipeline of submissions pending approval by ...
read more
Thursday, September 19, 2013
IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, today announced it has submitted its fourth abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company's ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the ...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its second abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings...
read more
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings ...
read more